New hope for hard-to-treat ovarian cancer: drug shrinks tumors in 40% of patients
NCT ID NCT07168083
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tests a drug called sacituzumab in 22 people with a rare and aggressive ovarian cancer (clear cell carcinoma) whose tumors grew after immunotherapy. The drug targets cancer cells and delivers chemotherapy directly to them. The main goal is to see if it can shrink tumors, with early data suggesting it may work better than standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.